Browsing Tag
AYVAKIT
5 posts
Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline
Sanofi doubles down on vaccines and rare immunology with Vicebio and Blueprint acquisitions. Find out how these deals could reshape its growth strategy.
Blueprint Medicines highlights long-term clinical and real-world data for Ayvakit at EHA and EAACI 2025
Blueprint Medicines presents strong long-term survival and safety data for Ayvakit in systemic mastocytosis at EHA and EAACI 2025. Explore the clinical and market impact.
Sanofi’s $9.5bn buyout of Blueprint Medicines signals high-stakes immunology expansion
Sanofi’s $9.5B Blueprint Medicines acquisition strengthens its rare disease pipeline with Ayvakit and signals deeper investment in immunology.
CHMP adopts positive opinion for avapritinib for PDGFRA D842V mutant GIST
US precision therapy company Blueprint Medicines said that the Committee for Medicinal Products for Human Use (CHMP) of…
FDA rejects Blueprint’s NDA for AYVAKIT for treatment of fourth-line GIST
Blueprint Medicines said that the US Food and Drug Administration (FDA) has rejected its new drug application (NDA)…